1. Home
  2. EBON vs CTXR Comparison

EBON vs CTXR Comparison

Compare EBON & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ebang International Holdings Inc.

EBON

Ebang International Holdings Inc.

HOLD

Current Price

$1.86

Market Cap

16.0M

Sector

Technology

ML Signal

HOLD

Logo Citius Pharmaceuticals Inc.

CTXR

Citius Pharmaceuticals Inc.

HOLD

Current Price

$0.68

Market Cap

18.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBON
CTXR
Founded
2010
2007
Country
China
United States
Employees
N/A
23
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.0M
18.7M
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
EBON
CTXR
Price
$1.86
$0.68
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
3.2K
699.3K
Earning Date
04-24-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
43.38
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$147.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.61
$0.47
52 Week High
$5.90
$2.19

Technical Indicators

Market Signals
Indicator
EBON
CTXR
Relative Strength Index (RSI) 42.86 55.70
Support Level $1.82 $0.49
Resistance Level $2.84 $0.74
Average True Range (ATR) 0.11 0.07
MACD -0.01 0.02
Stochastic Oscillator 48.28 47.70

Price Performance

Historical Comparison
EBON
CTXR

About EBON Ebang International Holdings Inc.

Ebang International Holdings Inc is engaged in blockchain technology and fintech, with activities also extending to the solar industry, supported by its application-specific integrated circuit (ASIC) chip designs. The Company's business mainly includes the sale of bitcoin mining machines and related accessories, telecommunication products, solar and battery storage products, cryptocurrency exchange services, cross-border payment and foreign exchange services, SaaS data visualization and analytics solutions, and rental services. It generates the majority of its revenue from cross-border payment and foreign exchange services, with its operations mainly in mainland China and Australia, which contribute the maximum revenue.

About CTXR Citius Pharmaceuticals Inc.

Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Share on Social Networks: